No Data
No Data
No Data
No Data
No Data
Intensity Therapeutics Got Nasdaq Letter Due To Resignation Of Daniel Donovan From Audit Committee, Co Not Compliant With Nasdaq Listing Rule 5605
Intensity Therapeutics Got Nasdaq Letter Due To Resignation Of Daniel Donovan From Audit Committee, Co Not Compliant With Nasdaq Listing Rule 5605
BenzingaApr 20 04:05
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) Shares
WESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today
GlobeNewswireMar 26 20:01
Intensity Therapeutics Price Target Maintained With a $12.00/Share by Benchmark
Intensity Therapeutics Price Target Maintained With a $12.00/Share by Benchmark
Dow JonesMar 21 22:16
Benchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target
Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics with a Speculative Buy and maintains $12 price target.
Analyst UpgradesMar 21 22:06
Intensity Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/21/2024 130.77% Benchmark → $12 Reiterates Speculative Buy → Speculative Buy 11/14/2023 130.77% Benchma
BenzingaMar 21 22:03
Intensity Therapeutics Reports FY23 EPS $(1.38) Vs $(2.22) YoY
Year-End 2023 Financial ResultsResearch and development expenses were $4.8 million for the year ended December 31, 2023, compared to $5.1 million for the same period in 2022. The decrease was primaril
BenzingaMar 15 04:29
No Data
No Data